In dyspeptic patients without gastric phase III of the migrating motor complex, Helicobacter pylori eradication produces no short-term changes in interdigestive motility pattern.
BACKGROUND
The relationship between Helicobacter pylori infection and interdigestive gastroduodenal motility in functional dyspepsia is still uncertain. Recent data from a large series documented that in dyspeptic patients without gastric phase III of the interdigestive migrating motor complex (MMC), the prevalence of bacterial infection was significantly higher. Since most H. pylori-positive dyspeptic patients have coexisting chronic gastritis, whether or not dyspepsia per se rather than bacterial colonization or chronic inflammation of the gastric mucosa may account for the observed interdigestive motility pattern is unknown. Our aim was to compare the interdigestive gastroduodenal motility pattern and dyspeptic symptoms before and 1 month after bacterial eradication in 20 H. pylori-positive dyspeptic subjects with chronic non-atrophic gastritis and without gastric phase III of the MMC, who were randomly allocated to receive eradication treatment (n = 10) or not (n = 10).


METHODS
Upper GI endoscopy with duplicate biopsies in antrum and corpus, 240-min interdigestive gastroduodenal manometric recording and symptoms assessment were performed before and 1 month after the treatments; bacterial eradication was confirmed by 13C-urea breath test.


RESULTS
After H. pylori eradication, neither in the incidence of antral and duodenal phase III of MMC nor in the phase II motility index values were any changes observed. Symptomatic improvement was recorded in both groups, with no significant differences between eradicated patients and controls.


CONCLUSIONS
In dyspeptic patients with chronic non-atrophic gastritis and without gastric phase III of MMC, H. pylori eradication influences neither the interdigestive motility pattern nor the symptoms in the short-term period.
Testoni
P A
PA
Dept. of Biomedical Sciences, University of Milan, and IRCCS San Raffaele Hospital, Italy.
Bagnolo
F
F
D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D001707:Biopsy, Needle; D001944:Breath Tests; D017291:Clarithromycin / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D004415:Dyspepsia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects*; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D016480:Helicobacter pylori / Q000187:drug effects*; D006801:Humans; D008297:Male; D008365:Manometry; D008875:Middle Aged; D009853:Omeprazole / Q000008:administration & dosage*; D011336:Probability; D018709:Statistics, Nonparametric; D014011:Tinidazole / Q000008:administration & dosage*; D014508:Urea
D014011:Tinidazole; D014508:Urea; D017291:Clarithromycin; D009853:Omeprazole